Skye Becomes a Shell for Redx: $125 Million Deal Hands Control to UK Fibrosis Company

Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.